Provided By GlobeNewswire
Last update: Mar 4, 2025
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, and Hans van Houte, chief financial officer of Nurix, will participate in the following conferences in March.
Read more at globenewswire.comNASDAQ:NRIX (7/2/2025, 3:26:54 PM)
12.55
+0.84 (+7.17%)
Find more stocks in the Stock Screener